Dr. Kurt Stoeckli, President & Chief Scientific Officer, Glenmark Pharmaceuticals ltd

Dr. Kurt Stoeckli

President & Chief Scientific Officer

Glenmark Pharmaceuticals ltd

Neuchatel, Switzerland

Links

https://fr.linkedin.com/in/kurt-stoeckli-33116b1

https://scrip.pharmamedtechbi.com/SC097931/ExSanofi-Exec-Stoeckli-Primes-Glenmarks-Cancer-Therapy-Ambitions

Having spent more than two decades in the pharmaceutical arena, Dr. Stoeckli has extensive industry experience and joins us from Sanofi where he was Group Vice President for Global Bio Pharmaceuticals Division. He was on their R&D Board, and served as CSO for R&D, France. In his tenure of more than fifteen years with Sanofi he has held progressive leadership positions of – Vice President, Global Head of Therapeutic Unit -Immuno-Inflammation, Vice President - Biological Sciences & Scientific Site Director, Vice President of Biological Sciences, Member of the Sanofi Aventis Discovery Board, Global Head of Discovery Technologies, and lastly Vice President, Global Lead Discovery, Aventis Pharma. Prior to joining Sanofi, Dr. Stoeckli worked for seven years in drug discovery at Novartis/Sandoz in Basel, Switzerland.

Dr. Stoeckli is Postdoctoral Fellow & Assistant Professor from Department of Biochemistry & Biophysics, University of California Medical Center and Ph.D., Cell Biology & Neurosciences from Max-Planck-Institute for Neurobiology.

Experience

President & Chief Scientific Officer

Glenmark Pharmaceuticals ltd

Neuchatel, Switzerland

oct 1 2016.............

Vice President Global Biotherapeutics

SANOFI

October 2012 – Present (4 years)Paris Area, France

Global responsibility within R&D for biologics from discovery up until phase 3 support across therapeutic areas

Deputy to President of Global R&D (ad interim) for Research & Early Development

Sanofi

March 2012 – September 2012 (7 months)Paris Area, France

Global R&D Management

VP R&D Global Head Immuno-Inflammation Unit

sanofi-aventis

January 2010 – March 2012 (2 years 3 months)Paris - Bridgewater

Therapeutic area head (Research & Early Development) in the area of immune-mediated and chronic inflammatory diseases

Vice President Biological Sciences & Scientific Director Vitry-Alfortville-Evry Site

Sanofi

January 2009 – December 2009 (1 year)Paris Area, France

Global head of research biologics
Member of R&D board
Scientific Director of Vitry-Alfortville-Evry Site

VP Biological Sciences, Discovery Research

sanofi-aventis

August 2007 – December 2008 (1 year 5 months)Frankfurt Am Main Area, Germany

Responsibility for newly created research biologics with teams in Frankfurt, Paris, Toulouse, Bridgewater, Cambridge)

VP Lead Discovery Technologies

Sanofi Aventis

March 2000 – August 2007 (7 years 6 months)Frankfurt Area, Germany

Research Program Head

Novartis AG

January 1993 – March 2000 (7 years 3 months)Basel Area, Switzerland

Education

University of California, San Francisco

 

1990 – 1993

Max Planck Society

 

1987 – 1990

Universität Basel

Doctor of Philosophy (Ph.D.)

1983 – 1987

IMD Business School

 

2004

Harvard Business School

 

2003

INSEAD

 

2001

Eidgenössische Technische Hochschule Zürich

//////////

Dr.B Gopalan CSO & Executive Director, Drug Discovery Research, Orchid Chemicals and Pharmaceuticals Limited,

Gopalan B

Chief Scientific Officer,Drug Discovery Research, at Orchid Research Laboratories Limited,

 

 LINK

 http://182.73.176.174/chc/scientists/Dr_Gopalan.pdf

 https://in.linkedin.com/in/gopalan-b-b78b627


Dr.Balasubramanian Gopalan CSO & Executive Director, Drug Discovery Research, Orchid Chemicals and Pharmaceuticals Limited, Sholinganallur, Chennai.

Email: drbgopalan@yahoo.co.in

Dr.Balasubramanian Gopalan a Ph.D. in the year 1973 from University of Madras in Synthetic Organic Chemistry and worked as Post Doctoral fellow in Harvard University with Nobel laurite E.J.Corey and then switched over to the industry and joined Syntex Research Inc., California and Bristol-Myers Squibb in Newjersey, USA.

He returned to India in the year 1982 and headed drug discovery division of Boots Pharmaceuticals Ltd., Sun Pharma Advanced Research Centre, Glaxo Ltd., Glenmark Research Centre, Matrix Laboratories and finally join as Executive Director and Chief of Orchid Chemicals & Pharmaceuticals in the year 2008.

His achievements include discoveries of many new drugs that are in Phase-2 and Phase-3 clinical trial. Many of these discoveries such as Oglemilast (a novel PDE IV inhibitor) was out-licensed to Forest Laboratories, USA for US$190 million over a period of five years & also to Teijin of Japan for US$53 million.

Other of his drug melogliptin a new DPP4 for type 2 diabetes was out-licensed to Merck Germany for US$231 million.

He has been a visiting fellow and elected fellow of many academics and universities to his credit he has 50 international patents.

He shares his expertise by training local talents in drug discovery research from Orchid chemical & Pharmaceuticals Ltd., OMR, Chennai.

Experience

Chief Scientific Officer,Drug Discovery Research,

Orchid Research Laboratories Limited,

CSO

Orchid Chemicals and Pharmaceuticals Ltd

2008 – Present (8 years)

Education

University of Madras

1970 – 1976

ICOS21, IIT BOMBAY, DEC 2016

DR B GOPALAN, CSO & Executive Director,
Drug Discovery Research, Orchid Chemicals and
Pharmaceuticals Limited,Sholinganallur,Chennai. — with DR B GOPALAN, ORCHID.

////////////

Rosana Kapeller, M.D., Ph.D., Chief Scientific Officer

 

 

Rosana Kapeller, M.D., Ph.D., Chief Scientific Officer

Dr. Rosana Kapeller is Chief Scientific Officer of Nimbus Therapeutics and holds responsibility for advancing the company’s programs from discovery to early human proof-of-concept. In addition to spearheading Nimbus’ scientific vision, Dr. Kapeller co-led the Series A funding for the company in 2011 and has worked closely with other members of the management team to create multiple strategic business opportunities for the company, including partnerships and collaborations with Schrodinger, Monsanto, Shire and Genentech. Before joining Nimbus, Dr. Kapeller was Vice President of Research and a Co-Founder of Aileron Therapeutics, where she led the development of that company’s “Stapled Peptide” technology. Under her leadership, Aileron secured $60 million in venture financing over its first four years. Prior to co-founding Aileron, Dr. Kapeller held positions of increasing responsibility at Millennium Pharmaceuticals, most recently serving as Director, Molecular and Cellular Biology. Dr. Kapeller earned her M.D. from Rio de Janeiro State University in Brazil, and her Ph.D. from Tufts University Medical School. She conducted her post-doctoral research work at the Dana-Farber Cancer Institute where she was named a David Abraham Fellow in Pediatric Oncology. In 2012, Dr. Kapeller was named one of the Top 20 Women to Watch by Mass High Tech. She currently serves as a scientific advisor to Atlas Venture.

 
 LINKS
 https://www.linkedin.com/in/rosana-kapeller-50231b

 https://twitter.com/kapellerrosana
 https://www.facebook.com/rosana.kapellerlibermann

Experience

CSO

Nimbus Discovery

February 2010 – Present (6 years 3 months)

Consultant

Third Rock Ventures

November 2009 – February 2010 (4 months)

Vice President of Research

Aileron Therapeutics

August 2005 – September 2009 (4 years 2 months)

Director

Millennium Pharmaceuticals

August 2002 – July 2005 (3 years)

Scientist/ Sr. Scientist

Millennium Pharmaceuticals

April 1996 – August 2002 (6 years 5 months)

Education

Tufts University

PhD, Molecular and Cellular Physiology

September 1987 – May 1994

UERJ

MD, Medicine

January 1980 – December 1986

 

How to Get to the Senior Levels of Scientific Management
#WESTpanel

Join us for a thought-provoking discussion on successful strategies for women in reaching top management in the sciences. A dynamic panel of women leaders will share their successes, and more importantly their lessons learned, as they have moved up the career ladder in scientific management. Come hear the wisdom of women leaders as they provide candid feedback and insightful advice on what enables women to reach the top.

Panelists: 

Rosana Kapeller, M.D., Ph.D., Chief Scientific Officer at Nimbus Therapeutics Rosana Kapeller is the Chief Scientific Officer of Nimbus Therapeutics and has more than 20 years of leadership experience in the biotechnology industry. Prior to joining Nimbus, she was Co-Founder and Vice President of Research of Aileron Therapeutics, where she led the development of Aileron’s “Stapled Peptide” technology. Under her scientific leadership, Aileron secured $60 million in venture financing over its first four years. Prior to co-founding Aileron, Dr. Kapeller held positions of increasing responsibility at Millennium Pharmaceuticals, most recently serving as Director, Department of Molecular and Cellular Biology. She earned her M.D. from Rio de Janeiro State University in Brazil, and her Ph.D. from Tufts University Medical School. She conducted her post-doctoral research work at the Dana-Farber Cancer Institute where she was named a David Abraham Fellow in Pediatric Oncology. Dr. Kapeller has published extensively and filed more than 150 patent applications, of which 50 have been issued. In 2012, Dr. Kapeller was named one of the Top 20 Women to Watch by Mass High Tech.

///////

Shahar Keinan, Chief Scientific Officer and Cofounder at Cloud Pharmaceuticals

Shahar Keinan

Chief Scientific Officer and Cofounder at Cloud Pharmaceuticals

Background

Dr. Shahar Keinan, Ph.D., co-founded Cloud Pharmaceuticals, Inc., in 2009 and serves as its Chief Scientific Officer. Dr. Keinan has extensive experience in the field of computational and theoretical chemistry. She has been instrumental in the development of the novel Inverse Design technology since its inception at Duke University, and has pioneered the use of the Inverse Design algorithm to optimize electro-optical materials and protein inhibitors. She has published over 25 peer-reviewed research articles. She leads the development and deployment of Inverse Design and Protein Symphony. She oversees the technical staff of TeraDiscoveries. She serves as Director of Cloud Pharmaceuticals. She obtained a Ph.D. in theoretical chemistry and a B.S. in Chemistry from The Hebrew University of Jerusalem.

LINKS
http://www.cloudpharmaceuticals.com/dr-shahar-keinan.html
https://www.linkedin.com/in/shahar-keinan-9b729b1
https://www.facebook.com/shahar.keinan.5/about
 https://plus.google.com/104847823339870075169/about

Dr. Shahar Keinan

Shahar Keinan, Ph. D.
Chief Scientific Officer (CSO) and CofounderShahar Keinan is the Chief Scientific Officer and co-founder of Cloud Pharmaceuticals. She has over 20 years of extensive experience in the field of computational and theoretical chemistry. Shahar has received a Ph.D. in theoretical chemistry from The Hebrew University of Jerusalem and has numerous papers and presentations in the fields of in-silico drug design and discovery, as well as molecular materials design and computational methods development.Shahar has been instrumental in the development of the novel Quantum Molecular Design process since its inception at Duke University, and has pioneered the use of the Quantum Molecular Design algorithm to optimize electro-optical materials and protein inhibitors. Currently, she leads the development and deployment of Quantum Molecular Design and oversees the technical staff of Cloud Pharmaceuticals.esign and computational methods development.
Shahar has been instrumental in the development of the novel Quantum Molecular Design process since its inception at Duke University, and has pioneered the use of the Quantum Molecular Design algorithm to optimize electro-optical materials and protein inhibitors. Currently, she leads the development and deployment of Quantum Molecular Design and oversees the technical staff of Cloud Pharmaceuticals.

Experience

Chief Scientific Officer and Cofounder

Cloud Pharmaceuticals

January 2008 – Present (8 years 3 months)RTP, NC

Cloud Pharmaceuticals (previously TeraDiscoveries, Inc.) designs new drugs and drug candidates and accelerates the development process by implementing new, innovative cloud computing technology in place of traditional methods.

Cloud Pharmaceuticals

Theory Staff Scientist at the UNC EFRC

University of North Carolina at Chapel Hill

September 2011 – October 2014 (3 years 2 months)

Post-Doctoral fellow

Duke University

January 2004 – September 2011 (7 years 9 months)

Inter-protein electron transfer
Inverse design of NLO materials
Inverse design of drugs

With Prof. Weitao Yang and Prof. David N. Beratan
Preformed theoretical design of organic molecules with high non-linear optical response (hyperpolarizability) properties, using inverse design methodologies.
Designed quinoid inhibitors for Cdc25 phosphatase, with potential as cancer drugs.

Post-Doctoral Fellow

Northwestern University

2001 – 2004 (3 years)Evanston, IL

Design of NLO materials
Theoretical Chemistry group
With Prof. Mark Ratner
Collaborating with the experimental group of Prof. Tobin Marks
Department of Chemistry

Education

The Hebrew University

PhD, Chemistry

1994 – 2000

Advisor: Prof. David Avnir
Thesis title: “The Applications of the Continuous Symmetry and Chirality Measures”

The Hebrew University of Jerusalem

B.S, Chemistry

1991 – 1994

 

Honors & Awards

Additional Honors & Awards

2002 The Junior Researcher Award from the Lise-Meitner Minerva Center, Israel.
2001 The R. Levine Prize of the Israeli Chemical Society for outstanding chemistry graduate.
1994 The Kenet Prize for Educational Merit in Undergraduate studies.

Shahar Keinan, PhD, Postdoc 2004-2011
CEO and founder Cloud Pharmaceuticals Compan

CSO Shahar Keinan and BOD Lex Van Der Ploeg at #ACSBoston Look for @CloudPharm at these events http://bit.ly/1b7BPsS 

//////